Taysha Gene Therapies Announces Collaboration with AllStripes on SURF1-Associated Leigh Syndrome Cli

DALLAS--(BUSINESS WIRE)-- Taysha Gene Therapies, Inc., (NASDAQ: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced a multi-year collaboration with AllStripes (formerly RDMD), a healthcare technology company dedicated to accelerating research for patients with rare diseases, during which Taysha will leverage AllStripes’ platform to inform its understanding of SURF1-associated Leigh syndrome natural history and burden of disease, as well as patients’ diagnostic journeys.


You can read the full article here.

7 views0 comments